Application of LncRNA-PRNCR1 in preparation of medicine for treating hemorrhagic shock

Through inhibitors or silencing agents of LncRNA-PRNCR1 and TRPM7, oxidative stress and inflammation are regulated, and the adverse reactions and oxidative stress damage in hemorrhagic shock treatment are solved, which significantly improves myocardial injury and acid-base imbalance, and protects blood vessels Endothelial cells reduce the secretion of apoptosis and inflammatory mediators.

CN118987223APending Publication Date: 2024-11-22浙江百越生物技术有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411125937.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the treatment of hemorrhagic shock, adverse reactions caused by the prior art, such as reduced hemoglobin concentration, coagulation dysfunction, reperfusion injury and immune dysfunction, and hemorrhagic shock and fluid resuscitation are prone to oxidative stress damage to vascular endothelial cells, affecting Treatment effect.

Method used

Using inhibitors or silencing agents of LncRNA-PRNCR1, the expression of miR-495 and TRPM7 is regulated by regulating oxidative stress and inflammation, combined with inhibitors or silencing agents of TRPM7, to protect endothelial cells and reduce apoptosis and inflammation mediators. Secretion, improve mean arterial pressure and acid-base imbalance.

Benefits of technology

Effectively reduce the area of ​​myocardial infarction and tissue damage caused by hemorrhagic shock, reduce the level of inflammatory factors, restore blood indicators to normal range, protect vascular endothelial cells, reduce cell apoptosis and the secretion of inflammatory mediators, and improve oxidative stress indicators.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004996413520000061
    Figure BDA0004996413520000061
  • Figure BDA0004996413520000071
    Figure BDA0004996413520000071
  • Figure BDA0004996413520000091
    Figure BDA0004996413520000091
Patent Text Reader

Abstract

The invention relates to the technical field of medicine, in particular to application of LncRNA-PRNCR1 in preparation of a medicine for treating hemorrhagic shock, provides a new molecular target for clinical treatment of HS / R, and provides a certain protection effect on oxidative stress of endothelial cells by silencing TRPM7 which has antioxidant activity and has a certain protection effect on oxidative stress and LncRNA-PRNCR1 regulation effect on oxidative stress, so that the application of the LncRNA-PRNCR1 in preparation of a medicine for treating hemorrhagic shock is realized, and the application of the LncRNA-PRNCR1 in preparation of a medicine for treating hemorrhagic shock. The silent LncRNA-PRNCR1 has a great inhibition effect on oxidative stress injury and inflammation caused by HS (Hepatosis Syndrome).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of LncRNA-PRNCR1 in preparing a medicine for treating hemorrhagic shock. Background Art

[0002] Hemorrhagic shock (HS) refers to a large amount of blood loss in a short period of time, which reduces the effective circulating blood volume, leads to insufficient oxygen supply to organs and tissues throughout the body, causes damage to the function of multiple organs, and even failure, threatening the patient's life. Therefore, fluid resuscitation should be taken in time to correct the patient's hypovolemia and improve the prognosis before surgical treatment. However, clinical studies in recent years have found that before patients take effective hemostatic measures, the use of large doses of fluid resuscitation will produce many adverse reactions, such as reduced hemoglobin concentration leading to weakened tissue oxygen supply, coagulation disorders, reperfusion injury, and abnormal immune function. At the same time, hemorrhagic shock and fluid resuscitation (HS / R) can easily cause oxidative stress damage to vascular endothelial cells, so when patients are treated for hemorrhagic shock, other injuries are often caused. Summary of the invention

[0003] In order to overcome at least one of the defects of the prior art described above, the present invention provides the use of LncRNA-PRNCR1 in the preparation of a drug for treating hemorrhagic shock, which can solve the problem of many adverse reactions in the treatment of hemorrhagic shock.

[0004] The technical solution adopted by the present invention to solve the problem is:

[0005] Application of LncRNA-PRNCR1 in the preparation of drugs for the treatment of hemorrhagic shock.

[0006] Furthermore, the application is the application of LncRNA-PRNCR1 to regulate oxidative stress and / or inflammation to treat hemorrhagic shock.

[0007] Furthermore, the object of application is rats.

[0008] The present invention also provides a medicine for treating hemorrhagic shock, wherein the medicine contains an inhibitor of LncRNA-PRNCR1 and / or a silencing agent of LncRNA-PRNCR1.

[0009] Furthermore, the LncRNA-PRNCR1 inhibitor and / or the LncRNA-PRNCR1 silencing agent is used to treat hemorrhagic shock by regulating oxidative stress and / or inflammation.

[0010] Furthermore, the inhibitor of LncRNA-PRNCR1 is a small interfering RNA of LncRNA-PRNCR1, an RNA interference vector of LncRNA-PRNCR1, or an antisense oligonucleotide corresponding to LncRNA-PRNCR1.

[0011] The present invention also provides a medicine for treating hemorrhagic shock, wherein the medicine contains a TRPM7 inhibitor and / or a TRPM7 silencing agent.

[0012] Furthermore, the TRPM7 inhibitor and / or the TRPM7 silencing agent is used to treat hemorrhagic shock by regulating oxidative stress and / or inflammation.

[0013] Furthermore, the TRPM7 inhibitor is an antibody against TRPM7;

[0014] The TRPM7 silencing agent is a small interfering RNA of the TRPM7 gene and / or an RNA interference vector of the TRPM7 gene.

[0015] In summary, the present invention provides a method having the following technical effects:

[0016] 1. The present invention provides a new molecular target for the clinical treatment of HS / R, and has antioxidant activity by silencing TRPM7, which has a certain protective effect on the oxidative stress of endothelial cells;

[0017] 2. The regulatory effect of LncRNA-PRNCR1 on oxidative stress. Silencing LncRNA-PRNCR1 has a significant inhibitory effect on oxidative stress damage and inflammation caused by HS;

[0018] 3. Improve the decrease in mean arterial pressure (MAP) in patients with hemorrhagic shock / fluid resuscitation (HS / R) by inhibiting or silencing LncRNA-PRNCR1. And restore the decrease in bicarbonate (HCO3-) level and the increase in lactate level in the blood after HS / R treatment to the normal range, thereby improving acid-base imbalance;

[0019] 4. Inhibition or silencing of LncRNA-PRNCR1 can reduce the area of ​​myocardial infarction caused by HS / R, improve myocardial tissue damage, reduce fibrosis, inflammatory cell infiltration and edema gaps, and also reduce the number of apoptotic cells;

[0020] 5. Inhibition or silencing of LncRNA-PRNCR1 can reverse the increased levels of malondialdehyde (MDA) caused by HS / R, which is a marker of oxidative stress, and can also increase the levels of glutathione (GSH) and superoxide dismutase (SOD), both of which are important antioxidants.

[0021] 6. Inhibition or silencing of LncRNA-PRNCR1 can inhibit the increase of inflammatory factors such as tumor necrosis factor (TNF-α) and interleukin-6 (IL-6).

[0022] 7. The expression of miR-495 and TRPM7 can be regulated by inhibiting or silencing LncRNA-PRNCR1. Silencing LncRNA-PRNCR1 can protect vascular endothelial cells from oxidative stress damage, reduce cell apoptosis, reduce the release of lactate dehydrogenase (LDH), reduce the secretion of inflammatory mediators, and inhibit the phosphorylation of NF-κB. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Effects of SiPRNCR1 treatment on MAP and metabolic acidosis in the HS / R rat model.

[0024] Figure 2 .Effect of silencing PRNCR1 on myocardial injury in HS / R rat model.

[0025] Figure 3 .MiR-495 is a target gene of PRNCR1.

[0026] Figure 4 Regulation of the PRNCR1 / miR-495 axis in HUVECs damaged by oxidative stress.

[0027] Figure 5 .TRPM7 is a target gene of miR-495.

[0028] Figure 6 Regulation of miR-495 / TRPM7 axis in HUVECs injured by oxidative stress. DETAILED DESCRIPTION

[0029] For better understanding and implementation, the technical solutions in the embodiments of the present invention will be clearly and completely described and discussed below in conjunction with the accompanying drawings of the present invention. Obviously, what is described here is only a part of the examples of the present invention, not all the examples. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0030] In order to facilitate the understanding of the embodiments of the present invention, the following will be further explained by taking specific embodiments as examples in conjunction with the drawings, and each embodiment does not constitute a limitation on the embodiments of the present invention.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0032] Embodiment 1:

[0033] Regarding the application of LncRNA-PRNCR1 in fluid resuscitation of severe hemorrhagic shock in rats, the specific experimental methods are as follows:

[0034] 1. Materials and Methods

[0035] 1. Experimental Animals

[0036] Thirty-six Sprague-Dawley rats (male) were ordered from Guangdong Medical Laboratory Animal Center (China). The rats were 8–9 weeks old, weighed 300–360 g, and were housed under specific pathogen-free conditions, with room temperature maintained at 20 ± 2 °C and a normal cycle (12 h light / 12 h dark), with free access to food and sterile tap water.

[0037] 2. Establishment of the Ischemia-Reperfusion Model Induced by HS / R

[0038] The HS rat model was established as described previously. Before the experiment, the rats were fasted for 12 hours (h). Then, the rats were anesthetized by intraperitoneal injection of 45 mg / kg sodium pentobarbital (P-010, Merck, Germany), and their femoral arteries were isolated and cannulated with polyethylene catheters. Subsequently, their left femoral arteries were connected to a multi-channel physiological signal acquisition and processing system (BIOPAC, Goleta, China) and blood pressure (mean arterial pressure, MAP) and heart rate were detected, while the right femoral artery was used to control bleeding. The left jugular vein was cannulated with a PE-50 tube for fluid resuscitation. The total blood loss rate was controlled at 45%, the bleeding time was controlled within 1 hour, and then the blood flowing out of the left femoral artery was perfused back into the rat within 40 minutes (min).

[0039] As described previously, rats were subcutaneously injected with phosphate-buffered saline (PBS) (A610100, China) containing small interfering RNA targeting PRNCR1 (siPRNCR1) or its negative control (siNC) 2 hours before surgery. After 6 hours of rescue, blood samples were collected and centrifuged (3000g, 15 minutes). The obtained serum was stored at -80°C. After the rats were euthanized, their heart tissues were collected.

[0040] The experimental animals were randomly divided into 6 groups, with 6 mice in each group (sham operation group, model group, sham operation + siNC group, sham operation + siPRNCR1 group, model + siNC group and model + siPRNCR1 group). Sham operation rats received anesthesia and surgery, but did not receive bloodletting.

[0041] 3. Blood gas analysis

[0042] Anticoagulated whole blood samples were collected 2 hours after resuscitation, and the bicarbonate (HCO3-) and lactate levels in the blood were measured using a blood gas analyzer (ABL800 FLEX, Radiometer, Denmark).

[0043] 4. Evans blue / TTC double staining

[0044] The inferior vena cava of the modeling rat was perfused with 2mL 3% Evans blue solution (A602025, Sangon, China). When the upper limbs and ears of the rat turned blue, the heart was quickly removed and repeatedly rinsed with normal saline. After cleaning, the heart tissue was cut into 4-5 slices, each with a thickness of 2 mm. It was stained with 1.5% TTC (A610558, Sangon, China) for 15 minutes, and then fixed with 10% neutral formaldehyde solution (E672001, Sangon, China). After imaging the stained slices under a fluorescence microscope, the infarct area (white area), ischemic area (red area) and normal area (blue area) were analyzed and calculated by AlphaEaseFC image processing software.

[0045] 5. Hematoxylin and Eosin (H&E) Staining

[0046] The collected heart tissue was fixed with 10% neutral formalin solution (BL-G001, Senbeijia, China), then embedded in paraffin and made into 5 μm thick sections. H&E kit (BP-DL001, Senbeijia, China) was used for staining after the sections were dewaxed and hydrated. After the sections were dehydrated and transparentized, they were sealed with neutral resin mounting medium (SBJ-0700, Senbeijia, China). The degree of damage to the rat myocardial tissue was observed under a microscope (AE2000, Motic, China, 100 times).

[0047] 6. TUNEL staining

[0048] TUNEL apoptosis detection kit (C1091, Beyotime, China) was used for TUNEL staining of cardiac tissue. After degreasing, hydration, proteinase K treatment and incubation with hydrogen peroxide (H2O2, 216763, Merck, Germany), the paraffin sections were incubated with 50 μL of biotin labeling solution. After washing, the sections were incubated with stop solution for 10 minutes. After that, streptavidin-HRP working solution and DAB solution were added to the sections in sequence. Next, the sections were stained for nuclear staining with hematoxylin staining solution. After dehydration, clearing and mounting, the sections were finally observed under a microscope at 200 times magnification.

[0049] 7. Detection of malondialdehyde (MDA), glutathione (GSH) and superoxide dismutase (SOD)

[0050] The MDA, GSH and SOD contents in rat serum were determined using an MDA assay kit (SBJ-R0007, Senbeijia, China), a GSH assay kit (BC1175, Solarbio, China) and a SOD assay kit (BC0170, Solarbio, China). In short, the standard solution first needs to be diluted into different concentration gradients to prepare for the subsequent standard curve drawing. After that, the diluted serum is added to a 96-well plate coated with antibodies in advance. Different reagents are then added to the 96-well plate according to the instructions. The absorbance is measured at 450 nm (MDA), 412 nm (GSH) or 560 nm (SOD) using a microplate reader (CMaxPlus, China), and the concentration of MDA, GSH or SOD is calculated according to the standard curve.

[0051] 8. Cell Culture and Treatment

[0052] Human umbilical vein endothelial cells (HUVECs, CL-0122, Procell, China) were grown in RPMI-1640 medium (72400120, Thermo Fisher, USA) containing 10% fetal bovine serum (FBS) (10091, Thermo Fisher, USA) and 1% penicillin-streptomycin (15140-122, Thermo Fisher, USA), and then cultured at 37°C, 5% CO2. HUVECs were treated with 400 μM H2O2 for 4 hours to establish an oxidative stress injury model of endothelial cells as described previously.

[0053] 9. QRT-PCR

[0054] Total RNA was extracted from rat heart tissue or HUVECs using a total RNA extraction kit (EZB-RN4, HiFunBio, China) or a miRNA extraction kit (EZB-miRN1, HiFunBio, China). Reverse transcription and qPCR of miR-495 were performed by a microRNA reverse transcription kit (EZB-miRT3, HiFunBio, China) and a qPCR mixture (EZB-miQP1, HiFunBio, China), while reverse transcription and qPCR of other RNAs were performed by a one-step qRT-PCR kit (AE341, Trans, China) using a real-time PCR detection system (CFX Connect, Bio-rad, USA). Data were obtained using 2 -ΔCt GAPDH (for lncRNA and mRNA) or U6 (for miRNA) was used as an internal control. The details of the primers are shown in Table 1:

[0055] Table 1. Primer sequence list

[0056]

[0057]

[0058] 10. Transfection

[0059] SiPRNCR1 (siB1494131505-1-5), siTRPM7 (siG000054822A-1-5) and siNC (siN0000002-1-5) were purchased from Ribobio (China). Meanwhile, miR-495 mimics (M, B01001), mimic control (MC, B04001), inhibitor (I, B03001) and inhibitor control (IC, B04006) were synthesized by Genepharma (China). Cells were seeded in 6-well plates at a density of 4 × 106 cells per well. After 24 h, the above oligonucleotide sequences were transfected into the cells according to the experimental requirements with the help of transfection reagent (STF02, China). After 24 h of transfection, the results were determined by qRT-PCR.

[0060] 11. Cell Treatment

[0061] In order to reveal the role of PRNCR1 / miR-495 axis in endothelial cells injured by oxidative stress, 6 groups of cells were set up: control group, H2O2 group, H2O2+siNC+IC group, H2O2+siPRNCR1+IC group, H2O2+siPRNCR1+I group, and H2O2+siNC+I group. The latter four groups of HUVECs were co-transfected with siNC / siPRNCR1 and miR-495I / IC and treated with H2O2.

[0062] Similarly, to explore the role of the miR-495 / TRPM7 axis in endothelial cells damaged by oxidative stress, we established 6 groups of cells: control group, H2O2 group, H2O2+IC+siNC group, H2O2+IC+siTRPM7 group, H2O2+I+siTRPM7 group, and H2O2+I+siNC group. The latter four groups of HUVECs were co-transfected with siNC / siTRPM7 and miR-495I / IC in HUVECs and treated with H2O2.

[0063] 12. Dual luciferase reporter assay

[0064] The wild-type (WT) and mutant (MUT) sequences of the binding sites predicted by starBase (http: / / starbase.sysu.edu.cn / ) were inserted into the psiCHECK-2 vector (kl-zl-1018, China Core Biotechnology Co., Ltd.), labeled as PRNCR1-WT (CAGAGGGGUUUUUUGUUU U), PRNCR1-MUT (CAGAGGGGUUUUUUGCAUU), TRPM7-WT (AGG AUCUCAUUUGACUUU), and TRPM7-MUT (AGGAUCUCAUUUGACUU GGCUU). These vectors were then co-transfected into cells with miR-495M or MC using a transfection reagent. After 24 hours of transfection, the changes in luciferase activity were measured using a dual-luciferase reporter system (E1910, Promega, USA) and a microplate reader.

[0065] 13. Cell Viability

[0066] Cell viability was measured using an MTT assay kit (SBJ-0191, Senbeijia, China). Specifically, treated cells (3 × 10 3 Each well was first reacted with 10 μL of MTT solution for 4 hours, and then 110 μL of Formazan solution was used to dissolve the crystals in each well. The absorbance at 490 nm was measured using a multiplex detection reader to calculate the relative viability of the cells.

[0067] 14. Apoptosis

[0068] Cell apoptosis was determined by Annexin V-FITC apoptosis detection kit (CA1020, Solarbio, China). 6) were first resuspended with binding buffer. The cell suspension was then incubated with 5 μL of Annexin V-fluorescein isothiocyanate reagent in the dark at room temperature for 10 min. Subsequently, the cell suspension was incubated with 5 μL of propidium iodide under the same conditions for 5 min. The volume of the cell suspension was supplemented to 500 μL with PBS, and then apoptosis was detected by flow cytometry (Accuri C6, BD, USA).

[0069] 15. Determination of lactate dehydrogenase (LDH) release

[0070] The LDH cytotoxicity detection kit (C0017, Beyotime, China) was used to evaluate the release of LDH in different groups. After the cells were treated differently, 60 μL of LDH detection working solution was added to each well and incubated for 30 minutes. The absorbance at 490 nm was detected by a multiplex detector to calculate the LDH content.

[0071] 16. Enzyme-linked immunosorbent assay (ELISA).

[0072] Tumor necrosis factor (TNF)-α and interleukin (IL)-6 in cell supernatants were determined using human TNF-α ELISA kits (SBJ-H0038, Senbeijia, China) and human IL-6 ELISA kits (SBJ-H0465, Senbeijia, China). More specifically, the supernatant of the cells was collected and diluted, and standard dilutions were prepared. The diluted samples or standards were added to a 96-well plate and incubated for 90 minutes. Subsequently, different reagents were added to the 96-well plate according to the instructions. The absorbance was measured at 450 nm using a microplate reader.

[0073] 17.Western blot

[0074] Using ExKine TM Total protein was extracted using a total protein extraction kit (KTP3006, Ablecon, China). The collected proteins were quantified, separated, electrophoresed, transferred, and blocked as described previously. After blocking with 5% BSA, the membrane was incubated with primary antibodies, and GAPDH was used as an internal control. After washing, the membrane was incubated with secondary antibodies. The detailed information of the antibodies is shown in Table 2. The protein bands were visualized using ECL Western Blotting Substrate (W028-2-1, Nanjing Jiancheng, China) on a gel imaging system (610020-9q, QinXiang, China), and the intensity of the protein bands was calculated using ImageJ2x (Rawak Software, Germany).

[0075] Table 2. Antibody information reference table

[0076]

[0077] 18. Statistical analysis

[0078] The results were analyzed using Graph Prism v8.0 (Graphpad Software, California, USA). Data are presented as mean ± SD. The expression of PRNCR1 between the sham group and the model group was analyzed by independent sample t test. One-way analysis of variance (ANOVA) was used for comparison among multiple groups. P < 0.05 was considered statistically significant.

[0079] 2. Results Analysis

[0080] 1.SiPRNCR1 improved the MAP decrease and acid-base imbalance in HS / R model rats.

[0081] The study found that the expression level of PRNCR1 in the heart tissue of rats in the model group was much higher than that in the prosthesis group ( Figure 1 A, P<0.001). Figure 1 As shown in B, the MAP of the model rats decreased significantly at the maximum blood loss (MBO), the beginning of resuscitation, and 1 and 2 hours after the end of resuscitation, but the MAP of the model rats treated with siPRNCR1 was improved after the end of resuscitation and 1 and 2 hours after the end of resuscitation ( Figure 1 B, P<0.05). In addition, the decreased bicarbonate (HCO3-) level and increased lactate level in the blood of rats after HS / R treatment were restored to normal levels by siPRNCR1 ( Figure 1 CD, P<0.001), indicating that siPRNCR1 improved the acid-base imbalance caused by HS / R.

[0082] 2. Silencing PRNCR1 has an inhibitory effect on HS / R-induced cardiac damage, cell apoptosis, oxidative stress and inflammation in rats.

[0083] Evans blue / TTC double staining results showed that the myocardial infarction area in the model+siNC group was larger than that in the sham+siNC group, while silencing PRNCR1 could reduce myocardial infarction caused by severe HS ( Figure 2 AB, P<0.001). Meanwhile, the results of H&E staining are shown in Figure 2 As shown in C, based on this result, we can observe that the model + siNC group has more fiber abnormalities, inflammatory cell infiltration, and a large number of edema gaps compared with the prosthesis + siNC group. In addition, silencing PRNCR1 can improve myocardial injury in the model group. Figure 2As shown in D, the brown nucleoli labeled by TUNEL represent apoptotic cells. After modeling, the number of apoptotic cells increased significantly, but siPRNCR1 could partially reverse the apoptosis caused by modeling. Afterwards, we evaluated the levels of MDA, GSH, and SOD in rat serum and found that the level of MDA in the serum of rats in the model+siNC group was significantly higher than that in the sham+siNC group, but the levels of GSH and SOD were lower than those in the sham+siNC group ( Figure 2 E, P<0.001). However, silencing PRNCR1 reversed the effects of modeling on MDA, GSH, and SOD levels ( Figure 2 E, P<0.01). Similarly, the increase of inflammatory factors TNF-α and IL-6 caused by modeling was also inhibited by siPRNCR1 ( Figure 2 F, P<0.001).

[0084] 3.MiR-495 is a target gene of PRNCR1.

[0085] The binding sites of PRNCR1 and miR-495 were predicted by starBase website ( Figure 3 A). It was found that miR-495M could reduce the luciferase activity of the PRNCR1-WT group, but could not affect the luciferase activity of the PRNCR1-MUT group, which once again proved the targeting relationship between PRNCR1 and miR-495 ( Figure 3 B, P<0.001). At the same time, the level of miR-495 in rat myocardial tissue was significantly lower than that before modeling, but this trend could be reversed by siPRNCR1 ( Figure 3 C, P<0.01). To explore whether PRNCR1 plays a role in oxidative stress in HUVECs by targeting miR-495, we transfected siPRNCR1 and miR-495I into HUVECs and determined the transfection efficiency by qRT-PCR ( Figure 4 AB, P<0.001). After HUVECs were exposed to H2O2 for 4 h, the level of PRNCR1 was greatly increased, while the level of miR-495 was decreased ( Figure 4 CD, P<0.001). Interestingly, the increase in PRNCR1 levels and the suppression of miR-495 levels induced by H2O2 could be reversed by siPRNCR1 ( Figure 4 CD, P<0.001).

[0086] 4.PRNCR1 / miR-495 axis regulates cell viability, apoptosis, oxidative stress, inflammation and activation of NF-κB pathway of HUVECs treated with H2O2.

[0087] H2O2 treatment resulted in cell viability ( Figure 4E, P<0.001) and SOD levels ( Figure 4 H, P<0.001) decreased, but was beneficial to cell apoptosis ( Figure 4 FG, P<0.001) and secretion of LDH ( Figure 4 H, P<0.001), TNF-α and IL-6 ( Figure 4 I, P < 0.001). However, these effects were reversed by siPRNCR1 and enhanced by miR-495I ( Figure 4 EI, P<0.01). In addition, co-transfection of siPRNCR1 and miR-495I could reverse the regulation of siPRNCR1 or miR-495I on the viability, apoptosis, and secretion of LDH, SOD, TNF-α, and IL-6 of HUVECs ( Figure 4 EI, P<0.01). We also found that H2O2 could induce NF-κB phosphorylation in HUVECs, which could be overturned by silencing PRNCR1 or promoted by miR-495I ( Figure 4 JK, P<0.01). However, co-transfection of siPRNCR1 and miR-495I could reverse the regulation of p-NF-κB protein level by siPRNCR1 or miR-495I ( Figure 4 JK, P<0.01). The same result was also found in the ratio between p-NF-κB and NF-κB ( Figure 4 L, P<0.001).

[0088] 5.TRPM7 is the target gene of miR-495.

[0089] Similarly, we predicted the binding sites of TRPM7 and miR-495 using an online website ( Figure 5 A). We then verified the targeting relationship between TRPM7 and miR-495 by dual luciferase reporter assay ( Figure 5 B, P<0.001). After transfection with siTRPM7, the expression of TRPM7 in HUVECs was significantly reduced ( Figure 5 C, P<0.001). Moreover, it was found that miR-495I could not only promote the level of TRPM7 in HUVECs induced by H2O2, but also reverse the downregulation of TRPM7 in HUVECs induced by H2O2 caused by siTRPM7 ( Figure 6 A, P<0.001).

[0090] 6. MiR-495 / TRPM7 axis regulates apoptosis, oxidative stress, inflammation, and activation of NF-κB pathway in HUVECs treated with H2O2

[0091] Compared with miR-495I, silencing of TRPM7 exerted a completely opposite effect, which was reflected in the inhibition of apoptosis of HUVECs treated with H2O2 ( Figure 6 BC, P<0.001), and decreased the levels of LDH, TNF-α and IL-6 ( Figure 6 DE, P<0.01, and increased the level of SOD ( Figure 6 D, P<0.001) and inhibited the phosphorylation of NF-κB ( Figure 6 FH, P<0.01). However, co-transfection of siTRPM7 and miR-495I reversed the regulatory effects of siTRPM7 or miR-495I on H2O2-treated HUVECs ( Figure 6 BH, P<0.05).

[0092] The technical means disclosed in the scheme of the present invention are not limited to the technical means disclosed in the above-mentioned implementation mode, but also include technical schemes composed of any combination of the above-mentioned technical features. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications are also regarded as the protection scope of the present invention.

Claims

1. Application of LncRNA-PRNCR1 in the preparation of drugs for the treatment of hemorrhagic shock.

2. Use of LncRNA-PRNCR1 according to claim 1 in preparing a drug for treating hemorrhagic shock, It is characterized in that The application is the application of LncRNA-PRNCR1 to treat hemorrhagic shock by regulating oxidative stress and / or inflammation.

3. Use of LncRNA-PRNCR1 according to claim 1 in preparing a drug for treating hemorrhagic shock, It is characterized in that The object of the application is rats.

4. A drug for treating hemorrhagic shock, It is characterized in that The medicine contains an inhibitor of LncRNA-PRNCR1 and / or a silencing agent of LncRNA-PRNCR1.

5. The drug for treating hemorrhagic shock according to claim 4, It is characterized in that The LncRNA-PRNCR1 inhibitor and / or the LncRNA-PRNCR1 silencing agent is used to treat hemorrhagic shock by regulating oxidative stress and / or inflammation.

6. The drug for treating hemorrhagic shock according to claim 4, It is characterized in that The inhibitor of LncRNA-PRNCR1 is a small interfering RNA of LncRNA-PRNCR1, an RNA interference vector of LncRNA-PRNCR1 or an antisense oligonucleotide corresponding to LncRNA-PRNCR1.

7. A drug for treating hemorrhagic shock, It is characterized in that The drug contains a TRPM7 inhibitor and / or a TRPM7 silencing agent.

8. The drug for treating hemorrhagic shock according to claim 7, It is characterized in that The TRPM7 inhibitor and / or the TRPM7 silencing agent is used to treat hemorrhagic shock by regulating oxidative stress and / or inflammation.

9. A method according to claim 7, It is characterized in that The TRPM7 inhibitor is an antibody against TRPM7; The TRPM7 silencing agent is a small interfering RNA of the TRPM7 gene and / or an RNA interference vector of the TRPM7 gene.